Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Mark FitzGerald

Showing results (161-170 of 325) with videos related to

Pageof 33
Sort By:
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|October 13, 2021
The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in CanadaMohsen Sadatsafavi, J Mark FitzGerald, Paul M O'Byrne, et al.
The Journal of Allergy and Clinical Immunology|December 15, 2019
Cost-effectiveness of implementing objective diagnostic verification of asthma in the United StatesMohsen Yaghoubi, Amin Adibi, Zafar Zafari, et al.
Journal of the American College of Cardiology|June 20, 2006
Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary diseaseG B John Mancini, Mahyar Etminan, Bin Zhang, et al.
BMC Pulmonary Medicine|May 21, 2009
Economic burden of asthma: a systematic reviewKatayoun Bahadori, Mary M Doyle-Waters, Carlo Marra, et al.
Respiratory Medicine|September 12, 2020
The cost-effectiveness of as-needed budesonide/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UKJ Mark FitzGerald, Sofie Arnetorp, Caitlin Smare, et al.
The Lancet. Respiratory Medicine|March 18, 2020
The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling studyAmin Adibi, Don D Sin, Abdollah Safari, et al.
Allergy|May 12, 2016
The asthma control in daily practiceG Ciprandi, M A Tosca, I Cirillo, et al.
BMC Infectious Diseases|November 17, 2016
Predictors of hospitalization of tuberculosis patients in Montreal, Canada: a retrospective cohort studyLisa A Ronald, J Mark FitzGerald, Andrea Benedetti, et al.
Immunotherapy|November 6, 2019
Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysisKevin Yan, Chakrapani Balijepalli, Rohini Sharma, et al.
The European Respiratory Journal|March 22, 2020
Avoiding immortal time bias in observational studiesAdam J N Raymakers, Mohsen Sadatsafavi, Don D Sin, et al.
Pageof 33

Showing results (161-170 of 325) with videos related to

Sort By:
Pageof 33
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|October 13, 2021
The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in CanadaMohsen Sadatsafavi, J Mark FitzGerald, Paul M O'Byrne, et al.
The Journal of Allergy and Clinical Immunology|December 15, 2019
Cost-effectiveness of implementing objective diagnostic verification of asthma in the United StatesMohsen Yaghoubi, Amin Adibi, Zafar Zafari, et al.
Journal of the American College of Cardiology|June 20, 2006
Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary diseaseG B John Mancini, Mahyar Etminan, Bin Zhang, et al.
BMC Pulmonary Medicine|May 21, 2009
Economic burden of asthma: a systematic reviewKatayoun Bahadori, Mary M Doyle-Waters, Carlo Marra, et al.
Respiratory Medicine|September 12, 2020
The cost-effectiveness of as-needed budesonide/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UKJ Mark FitzGerald, Sofie Arnetorp, Caitlin Smare, et al.
The Lancet. Respiratory Medicine|March 18, 2020
The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling studyAmin Adibi, Don D Sin, Abdollah Safari, et al.
Allergy|May 12, 2016
The asthma control in daily practiceG Ciprandi, M A Tosca, I Cirillo, et al.
BMC Infectious Diseases|November 17, 2016
Predictors of hospitalization of tuberculosis patients in Montreal, Canada: a retrospective cohort studyLisa A Ronald, J Mark FitzGerald, Andrea Benedetti, et al.
Immunotherapy|November 6, 2019
Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysisKevin Yan, Chakrapani Balijepalli, Rohini Sharma, et al.
The European Respiratory Journal|March 22, 2020
Avoiding immortal time bias in observational studiesAdam J N Raymakers, Mohsen Sadatsafavi, Don D Sin, et al.
Pageof 33